Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
167 USD | +0.44% | +0.28% | -7.09% |
May. 02 | UBS Adjusts Price Target on Repligen to $205 From $225, Maintains Buy Rating | MT |
May. 01 | Repligen's Q1 Adjusted Earnings, Revenue Fall | MT |
Financials (USD)
Sales 2024 * | 638M | Sales 2025 * | 740M | Capitalization | 9.33B |
---|---|---|---|---|---|
Net income 2024 * | 33M | Net income 2025 * | 89M | EV / Sales 2024 * | 14.1 x |
Net cash position 2024 * | 315M | Net cash position 2025 * | 420M | EV / Sales 2025 * | 12 x |
P/E ratio 2024 * |
286
x | P/E ratio 2025 * |
107
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.42% |
Latest transcript on Repligen Corporation
1 day | +0.44% | ||
1 week | +0.28% | ||
Current month | +1.74% | ||
1 month | -5.79% | ||
3 months | -14.84% | ||
6 months | +11.10% | ||
Current year | -7.09% |
Managers | Title | Age | Since |
---|---|---|---|
Tony Hunt
CEO | Chief Executive Officer | 60 | 14-04-30 |
Olivier Loeillot
PSD | President | 54 | 23-10-01 |
Jason Garland
DFI | Director of Finance/CFO | 50 | 23-09-24 |
Members of the board | Title | Age | Since |
---|---|---|---|
Karen Dawes
CHM | Chairman | 72 | 05-08-31 |
Director/Board Member | 58 | 14-06-11 | |
Martin Madaus
BRD | Director/Board Member | 64 | 23-02-05 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.43% | 5 M€ | -1.80% | - | |
1.01% | 0 M€ | 0.00% | - | |
0.84% | 0 M€ | 0.00% | - | |
0.55% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 167 | +0.44% | 454,984 |
24-05-02 | 166.3 | +5.02% | 848,499 |
24-05-01 | 158.4 | -3.56% | 909,297 |
24-04-30 | 164.2 | -1.17% | 756,816 |
24-04-29 | 166.1 | -0.26% | 426,055 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.09% | 9.33B | |
-3.79% | 184B | |
-0.84% | 108B | |
-3.75% | 67.8B | |
+3.45% | 51.05B | |
+9.04% | 44.67B | |
+3.40% | 41.78B | |
+3.66% | 26.59B | |
+3.21% | 26.78B | |
+15.23% | 25.86B |
- Stock Market
- Equities
- RGEN Stock